Log in to search using one of your social media accounts:

 

Mesothelioma Patients Live Longer After Aggressive Cancer Surgery

Aggressive pleurectomy/decortication surgery, while often recommended, will cause a significant decrease in pulmonary function with early-stage mesothelioma patients whose symptoms were previously minimal. More symptomatic patients with advanced disease will experience an improved quality of life and a preservation of their current pulmonary status after the same surgery. Those findings were reported in a study from the Department of Surgery, Division of Oncology at the University of Chicago Medical Center, raising questions about aggressive surgery for the early stages of mesothelioma. "Some of the results might be a little unexpected," renowned cardiothoracic surgeon Dr. Wickii Vigneswaran, told asbestos.com. "They gave us something to look closer at. They didn't change our thinking." The study was published last month in the Annals of Thoracic Surgery. Performance Status Is Key The P/D surgery involves the removal of the pleural lining around the lungs, as well as any visible tumors on the lungs or surrounding areas. The surgery also often involves partial or complete resection of the diaphragm, which is rebuilt with prosthetics. The study included 36 mesothelioma patients at the University of Chicago Cancer Center, all of whom had the P/D surgery performed by Vigneswaran, one of the country's leading thoracic surgeons. He also is well known for his expertise in thoracic organ transplants. There were 17 patients with a performance status (PS) of 0 at ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Every year, more people die from asbestos exposure than road traffic accidents in Great Britain. Many countries still continue to build with this lethal substance – but why?Hannah Devlin investigatesSubscribe and review onAcast,Apple Podcasts,Soundcloud,Audioboom andMixcloud. Join the discussion onFacebook andTwitterThe health effects of asbestos have been well documented for decades. Inhaling these fibres can cause mesothelioma, a very aggressive form of cancer with a poor prognosis. In Great Britain, more people die from this disease every year than road traffic accidents. And yet this material is still found in at...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Science Health Medicine Cancer research Medical research Society Source Type: news
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Systemic chemotherapy, either before or after cytoreductive surgery, provided no improvement in long-term survival for patients with peritoneal mesothelioma, according to a recent study. The addition of systemic chemotherapy improved survival at the one-year mark, but there were no benefits at the two-, three- or five-year checkpoints. Systemic chemotherapy uses anti-cancer drugs that are injected into a vein or given by mouth. The median survival of surgical patients who received systemic chemotherapy did not improve, either. “We know surgery is the best option, and if the surgery is successful, chemotherapy may not...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions: Targeting the epigenetic induction of DKK1 may lead to effective treatment of MM, and T3E has great potential to induce anti-MM activity.Pharmacology 2018;102:26 –36
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research
There is very little information available on the psychological care needs of people with malignant mesothelioma. Even less is known about people who have been exposed to asbestos but do not have mesothelioma. A newly published systematic research review sheds light on the distress people experience in these situations. In March 2018, the American Journal of Industrial Medicine published an article highlighting the need for additional studies. Researchers described what is known about asbestos-affected people and how and why they experience so much mental and emotional distress. Most Affected People Exposed Through Work Th...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Dr. Shanel Bhagwandin saw the steady flow of patients who traveled from Southeast Florida to New York’s renowned Mount Sinai Hospital for the specialized treatment of peritoneal mesothelioma cancer. He knew there was a better way, and he just made it happen. Bhagwandin made the 1,200-mile move himself — from Mount Sinai to the Jupiter Medical Center — to start the latest surgical oncology program that specializes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). “This procedure can make a tremendous difference,” Bhagwandin told Asbestos.com. “And it makes a ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Takehara Y, Yamochi T, Nagumo T, Cho T, Urushibara F, Ono K, Fujii T, Okamoto N, Sasaki Y, Tazawa S, Honma M, Norose T, Shiozawa E, Tate G, Takimoto M Abstract Gene mutations are involved in the development of malignant mesothelioma. Important mutations have been identified in the genes for cyclin-dependent kinase inhibitor 2A (p16) alternative reading frame, breast cancer-associated protein 1 (BAP1) and neurofibromatosis type 2 (NF2). Previously, the utility of detecting the loss of BAP1 by immunohistochemistry (IHC) and p16-deletion by fluorescence in situ hybridization has been identified in several stu...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Abstract Pemetrexed (PEM) is a novel and multi-targeted antifolate used as an antineoplastic agent for non-small cell lung cancer (NSCLC) and pleural mesothelioma. Although glucocorticoid was often used with PEM to reduce toxicity during the chemotherapy, it is not clear yet whether glucocorticoid co-administration could affect PEM efficacy in NSCLC. Here we established NSCLC cell lines and examined the effects of dexamethasone (DEX) on PEM sensitivity in vitro and in xenograft models. DEX co-administration reduced chemotherapy sensitivity to PEM in xenograft models. DEX co-administration promoted cell growth and ...
Source: Food and Chemical Toxicology - Category: Food Science Authors: Tags: Food Chem Toxicol Source Type: research
CONCLUSIONS:  Overall, anti-FAP-Δ-CD28/CD3ζ CAR T cells revealed superior in vitro functionality, better tumor control in combination with PD-1 blockade in humanized mice, and persistence up to 21 days in a MPM patient. Therefore, further clinical investigation of this optimized CAR is warranted. PMID: 29748183 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
It is common for cancer patients to experience fatigue during and after cancer treatment. Fatigue usually lessens as patients recover, but some patients experience long-term fatigue that gets in the way of the things they want to do. Mesothelioma survivors are among the many cancer patients who cope with fatigue once treatment ends. New research conducted by scientists at the University of Alabama at Birmingham and Harvard Medical School shows cancer-related fatigue can be relieved by a placebo pill. This relief even occurs when patients are aware they are taking a placebo, known as open-label placebo. A placebo is anythin...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular & Thoracic Surgery | Chemotherapy | Environmental Health | Health | Heart | Lung Transplant | Mesothelioma | Palliative | Palliative Care | Study | Transplants